Product Information
MEMANTINE HCL ER 7 MG CAPSULE is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.3123 per EA under NDC 16571085203. Its NADAC has been published 36 times since Jan 28, 2026.
FDA first approved this application on Sep 28, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the memantine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
7 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571085203
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MEMANTINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA206032FDA Approved
9/28/2016
TE Code
AB
On Market Since
6/1/2025
Pharmacological Classes
Price Statistics
The NADAC for MEMANTINE HCL ER 7 MG CAPSULE has been published 36 times since Jan 28, 2026, and over the history we have for it it has declined 14.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3123 per EA |
|---|---|
| All-time high | $0.3657 (Feb 11, 2026) |
| All-time low | $0.2946 (May 20, 2026) |
| 52-week high | $0.3657 |
| 52-week low | $0.2946 |
| Median price | $0.3206 |
| Average price | $0.3253 |
| Largest weekly change | -11.0% (Feb 18, 2026) |
| Weeks tracked | 36 |
| Tracking since | Jan 28, 2026 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the memantine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
memantine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
N-methyl-D-aspartate Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MEMANTINE HCL ER 7 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for MEMANTINE HCL ER 7 MG CAPSULE, manufactured by Rising Pharma Holdings Inc., is $0.3123 per EA (NDC 16571085203), effective Sep 30, 2026.
How has the price of MEMANTINE HCL ER 7 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for MEMANTINE HCL ER 7 MG CAPSULE has declined 14.6%. It has been tracked across 36 weekly CMS publications since Jan 28, 2026.
What are the highest and lowest recorded NADAC prices for MEMANTINE HCL ER 7 MG CAPSULE?
Since Jan 28, 2026, the NADAC for MEMANTINE HCL ER 7 MG CAPSULE has ranged from a low of $0.2946 (May 20, 2026) to a high of $0.3657 (Feb 11, 2026), with a median of $0.3206 per EA.
Are there cheaper alternatives to MEMANTINE HCL ER 7 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of MEMANTINE HCL ER 7 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures MEMANTINE HCL ER 7 MG CAPSULE?
MEMANTINE HCL ER 7 MG CAPSULE (NDC 16571085203) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.